Boehringer’s focus on Health Equity drives significant upgrade in Access to Medicine Index Ranking
19 nov. 2024 08h15 HE
|
Boehringer Ingelheim Limited
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has been lifted to 8th place in the 2024 Access to Medicine Index (ATMI), up from 13th in 2022. This improvement reflects the...